Please login to the form below
rheumatoid arthritis
This page shows the latest rheumatoid arthritis news and features for those working in and with pharma, biotech and healthcare.
Amgen wins Enbrel patent case, knocking back Sandoz's biosimilar plan
Sandoz won US Food and Drug Administration (FDA) approval for a biosimilar version of Amgen’s blockbuster rheumatoid arthritis drug in 2016 but has been unable to introduce the drug because
Latest news
-
White House unveils plans to reimport medicines from Canada
These limitations would severely restrict the impact of the plans, as these exemptions would include many of the most high cost drugs, such as rheumatoid arthritis drug Humira and cancer treatment
-
Dupixent drives Sanofi again, but other new drugs are lagging
There was a glimmer of acceleration for rheumatoid arthritis therapy Kevzara (sarilumab) which climbed 150% to 52m after several quarters of lacklustre performance.
-
Otezla scores new indication as speculation over potential buyers grows
Gilead is already working with Galapagos on oral anti-inflammation drug filgotinib, which is set for submission to regulators for rheumatoid arthritis by the end of this year.
-
Gilead strikes $5.1bn deal to bolster ties with Galapagos
rheumatoid arthritis. ... Filgotinib is however up against some tough competition in the market, from Pfizer’s blockbuster Xeljanz (tofacitinib) – already approved for RA, psoriatic arthritis and ulcerative colitis – as well as AbbVie’s
-
Citryll snares €15m backing for its autoimmune disease NETs
In some autoimmune disease such as lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis, it is thought that NETs inadvertently react to host cells, stimulating the release
More from news
Approximately 56 fully matching, plus 411 partially matching documents found.
Latest Intelligence
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... Dysfunction in the regulation of the JAK family of molecules is implicated in the aberrant production of
-
Drug launches to watch in 2019
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that
-
Finding the patient voice
rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.
-
The tipping point
In chronic diseases such as rheumatoid arthritis and inflammatory bowel disease, there are significantly greater savings from switching patients compared with initiating biosimilars in naïve patients alone.
-
Mobile health and patient outcomes
In a recent study in rheumatoid arthritis, patients saw pain as the key measure of treatment success, confounding the objective ‘clinical evidence’ of improvement.
More from intelligence
Approximately 0 fully matching, plus 35 partially matching documents found.
Latest appointments
-
Portland Health appoints Jamie Hewitt as an account director
He joins the firm from the National Rheumatoid Arthritis Society, where he was its head of government affairs, leading the policy and public affairs functions. ... During his time at the National Rheumatoid Arthritis Society, Hewitt ran UK campaigns to
-
Liberation Unlimited promotes Vicky Smith
oncology, rheumatoid arthritis and eye health.
-
Galapagos appoints Bart Filius as chief financial officer
His vast experience in big pharma and his sharp strategic view will help us bring Galapagos to the next level, as we prepare to have our rheumatoid arthritis molecule GLPG0634 enter
-
TiGenix appoints Dr Marie Paule Richard
In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is
-
Liberation promotes Danielle Smith to account director
Meanwhile, Vicky joined Liberation last year and in her new role will continue to work across a range of therapeutic areas including men's health, rheumatoid arthritis and eye health.
More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient. Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at twelve of the key indices captured in Therapy Watch data. Click here
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several
-
Report: Living With Rheumatoid Arthritis 2019 reports now available to purchase
We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada.
-
Report: Living with RA (EU, Japan and Canada) 2019 reports
Research Partnership launches new patient Living with Rheumatoid Arthritis (EU &Japan) 2019 report. ... The qualitative interviews will be enhanced with insights generated from pre-interview patient exercises – such as patient diary entries - to
-
NHS medicines optimisation milestone
for a population of patients with Rheumatoid Arthritis. To achieve this, pharma needs to consider issues such as treatment failure rates; inpatient stays, the impact on social care and a
More from PMHub
Approximately 8 fully matching, plus 17 partially matching documents found.
Featured jobs
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Account Director, Healthcare Communications
-
Salary TBC
- FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...
-
Excellent Daily Rate
- Account Director - Medical Communications - London / South East
-
Excellent Salary and Benefits on offer
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
Subscribe to our email news alerts
- The relevance of patient perspectives to value
- Sanofi patent case win holds off generic rivals for key cancer drug
- Leo Pharma to market AstraZeneca’s brodalumab outside Europe
- Regeneron scores positive data in phase 3 cholesterol trial
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Putting our core values into practice at the Porterhouse summer social
PMHub
Havas Life Medicom
We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...
Latest intelligence
- The relevance of patient perspectives to value
- Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
- How is the NHS Long-term Plan being put into action?
- Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
- The evolution of real-world studies
- How industry and regulators are using real-world data...
Quick links
Infographics
